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ABSTRACT
Zygomycosis is a rare but emerging mycosis. Because of the sub-optimal efficacy of the standard
antifungal treatment for this disease, hyperbaric oxygen (HBO) has been used occasionally as an
adjunctive therapeutic modality. A review of 28 published cases of zygomycosis indicates that
adjunctive HBO may be beneficial in diabetic patients (94% survival), whereas its benefit in the small
group of patients with haematological malignancies or bone marrow transplants is doubtful (33%
survival; p 0.02). Prolonged courses of HBO were associated with a higher survival (100% survival;
p 0.003). Additional studies are required to assess the optimal timing and dose for HBO treatment.
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Zygomycetes are important fungal pathogens of
humans [1]. Zygomycosis is caused by fungi of the
order Mucorales, most commonly Rhizopus,
Mucor, Absidia and Rhizomucor spp. [1]. These
organisms cause acute angioinvasive infections in
patients with a variety of immunosuppressive
conditions, including poorly controlled diabetes
mellitus (especially diabetic ketoacidosis), neu-
tropenia, malignancies, transplants, burns and
chronic renal failure, as well as those receiving
chronic immunosuppressive therapy and defer-
roxamine therapy. The most common manifesta-
tions of zygomycosis are sinusitis, pneumonia,
rhinocerebral infection, soft tissue infection and
disseminated disease [1]. In contrast, entomoph-
thoromycosis, the infection caused by zygomyc-
etes of the order Entomophthorales, mainly
Basidiobolus and Conidiobolus spp., manifests typ-
ically as chronic, subcutaneous infection; angioin-
vasion is not prominent and the prognosis is good
[2]. It should be noted at this point that recent
developments in fungal taxonomy have resulted
in the creation of a new order, Basidiobolales,
containing the single genus Basidiobolus, while
Conidiobolus forms part of a phylogenetically
distinct group that is related closely to other
zygomycetes such as Mucorales [3,4].
Zygomycosis has emerged as an increasingly
common invasive mould infection, particularly
among leukaemia patients and bone marrow
transplant (BMT) recipients [5]. Zygomycetes are
inherently resistant to most antifungal agents [1].
Amphotericin B is the only licensed antifungal
agent with activity against zygomycetes [1], but
amphotericin B therapy is often combined with
surgery because of the tissue infractions caused
by zygomycetes.
Since the 1970s, the successful use of hyperbaric
oxygen (HBO) as an adjunctive treatment for
zygomycosis has been documented in several
patients [6–10]. HBO inhibits fungal growth
in vitro at pressures greater than 10 atmospheres
absolute (ATA) [11]. It also corrects lactic acidosis,
thus promoting the oxidative action of amphoter-
icin B [12]. In addition to its antifungal activity,
HBO contributes to tissue healing by several
mechanisms. It can elevate tissue oxygen levels
significantly, which increases the rate of tissue
healing, and it enhances leukocyte-mediated pha-
gocytosis. It can also elevate significantly the
levels of growth factors, which promotes angio-
genesis and healing [12]. During HBO treatment,
100% oxygen is provided to patients in chambers
through facemasks, hood tents or endotracheal
tubes [13].
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A review of the literature identified 28 cases in
which zygomycosis was treated adjunctively with
HBO. Patients were diagnosed with zygomycosis
if zygomycetes were grown in culture from
the site of infection and ⁄ or histopathological
examination of infected tissue revealed broad,
branching, non-septate hyphae. There was a
predominance of male patients (n = 17; 61%),
and the mean age of the patients was 31 years
(range, 5 months to 74 years). Rhizopus (n = 11)
was the most common species isolated, followed
by Apophysomyces (n = 3), Mucor (n = 2) and
Absidia (n = 2). Of three patients with entomoph-
thoromycosis, two were infected with Conidiobolus
coronatus, and one with Conidiobolus incongruous.
Diabetes mellitus was present in 17 (61%)
patients, of whom ten (36%) also had ketoacido-
sis. Five (18%) patients developed zygomycosis
after trauma, two (7%) had alcoholic liver disease,
and one was receiving systemic corticosteroids.
Three (11%) patients had haematological malig-
nancies or BMT. Three (11%) patients had no
known risk factors for zygomycosis. The most
common site of infection was sino-orbito-cerebral
(n = 21; 75%). Other less common sites of infec-
tion included soft tissue (n = 4; 14%), lung (n = 2;
7%), kidney (n = 1; 4%), and sclera (n = 1; 4%).
There was one case of disseminated infection.
Most of the patients received two sessions of
HBO ⁄day, each lasting 90–120 min, at a pressure
of 2–3 ATA. The median number of sessions was
22 (range, 2–85). HBO was administered post-
operatively to most (23 ⁄ 25; 92%) patients who
also had surgery. Amphotericin B was used in all
except two cases.
The overall survival rate was 86% at the end of
treatment, with a survival rate among diabetic
patients of 94%. Two of three patients with an
underlying haematological malignancy or BMT
died (p 0.02; OR 48), compared with no deaths
among patients who developed the infection
following trauma or among patients with no
predisposing factors. Two of four patients with
fatal zygomycosis were infected with Rhizopus,
while one was infected with Apophysomyces. All
patients who died had sino-orbito-cerebral dis-
ease; there were no deaths in patients with
infection at other sites. Survivors received signi-
ficantly (p 0.009) more sessions of HBO therapy
than non-survivors (median 24 (range, 9–85) and
six (range, 2–9) sessions, respectively). Treatment
with nine or fewer sessions of HBO was associ-
ated with a greater risk of mortality (p 0.003;
OR 225).
The review revealed a high rate of survival
amongHBO-treated patients. Importantly, most of
the patients identified had correctable predispo-
sing conditions, such as diabetes or trauma, rather
than haematological malignancies or BMT, which
are associated with a greater risk of mortality. It is
also possible that patients who did not respond
to HBO treatment were under-reported, so the
high response rate may represent publication bias.
The improved survival rate among patients who
received more sessions of HBO probably repre-
sents a survival bias, since those who responded
to treatment were more likely to continue HBO,
while those who died early during therapy would
have had fewer sessions.
Previous small case series, comparing the mor-
tality rate of patients with sino-orbito-cerebral
zygomycosis, treated with or without HBO, have
concluded that patients treated with standard
therapy (amphotericin B and surgery) and HBO
were more likely to survive than patients treated
only with standard therapy [7,8]. In contrast, a
study of deferroxamine-induced zygomycosis in
mice failed to show a survival benefit in the group
of mice treated with HBO and amphotericin B,
compared to the group treated with amphotericin
B alone [14]. However, the hyperacute type
of infection caused by intravenous inoculation of
fungal spores, and the relatively low pressure of
the HBO administered, may account for this
study’s negative results.
In conclusion, HBO offers a theoretically prom-
ising approach for the treatment of zygomycosis.
However, current knowledge does not allow
definitive conclusions regarding the efficacy of
HBO, since individual case reports do not often
take into consideration the benefit of concomitant
correction of underlying metabolic factors or the
timing and extent of surgery. In the absence of
control groups for comparison, it is not yet
possible to define a group of patients who are
most likely to benefit from HBO.
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